XENE Xenon Pharmaceuticals Inc

Price (delayed)

$36.56

Market cap

$3.54B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.74

Enterprise value

$3.43B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical ...

Highlights
XENE's debt is down by 26% year-on-year and by 14% since the previous quarter
The company's equity has surged by 96% YoY but it fell by 7% QoQ
The quick ratio has grown by 40% YoY but it has contracted by 25% from the previous quarter
The company's revenue has shrunk by 100% YoY
Xenon Pharmaceuticals's gross profit has plunged by 100% YoY

Key stats

What are the main financial stats of XENE

XENE stock price

How has the Xenon Pharmaceuticals stock price performed over time
Intraday
-6.47%
1 week
-35.59%
1 month
-39.84%
1 year
-2.01%
YTD
-18.43%
QTD
-39.43%

Financial performance

How have Xenon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$441.59M
Net income
-$409.2M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
Xenon Pharmaceuticals's gross profit has plunged by 100% YoY
The net income has declined by 47% year-on-year and by 7% since the previous quarter
The operating income is down by 39% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does XENE's price correlate with its fundamentals

Growth

What is Xenon Pharmaceuticals's growth rate over time

Valuation

What is Xenon Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 34% YoY
The company's equity has surged by 96% YoY but it fell by 7% QoQ
XENE's price to book (P/B) is 39% lower than its last 4 quarters average of 5.0 and 16% lower than its 5-year quarterly average of 3.6
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Xenon Pharmaceuticals business performance
XENE's return on invested capital is down by 28% year-on-year but it is up by 17% since the previous quarter
Xenon Pharmaceuticals's return on assets has decreased by 14% YoY but it has increased by 10% QoQ
Xenon Pharmaceuticals's return on equity has decreased by 14% YoY but it has increased by 11% QoQ

Dividends

What is XENE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XENE.

Financial health

How did Xenon Pharmaceuticals financials performed over time
The total assets has soared by 92% year-on-year but it has declined by 7% since the previous quarter
The quick ratio has grown by 40% YoY but it has contracted by 25% from the previous quarter
XENE's debt is 99% smaller than its equity
The company's equity has surged by 96% YoY but it fell by 7% QoQ
XENE's debt is down by 26% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.